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cline proved cost-saving or cost effective in relation to the alter-
natives studied. Overall, a gain of about 78–200 thousand life
years (LYG) or 88–226 thousand quality-adjusted life years
(QALYs) can be obtained in a long-term. The incremental cost-
effectiveness ratio (ICER) is 2.330 EUR per LYG (2.073 per
QALY) and 1.781 EUR per LYG (1584 per QALY) compared to
unaided cessation or bupropion, respectively. Varenicline is a
dominant strategy compared to NRT. Even if the savings from
avoided smoking-related diseases are ignored and the time
horizon will be reduced to 20 years, varenicline remains cost-
effective with ICER under 18.000 EUR per LYG and QALY
compared to all other alternatives. CONCLUSION: The results
corroborate the ﬁndings of health beneﬁts and favourable cost-
effectiveness of smoking cessation pharmacotherapy from former
studies.
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OBJECTIVES: Prior to use in an international study, the Insulin
Treatment Satisfaction Questionnaire (ITSQ) and the Environ-
mental Tobacco Smoke Questionnaire (ETS-Q) underwent lin-
guistic validation in 10 and 6 languages respectively. The original
scales containing 22 and 3 items were developed in US and UK
English respectively. Rigorous methodology was required to
ensure conceptual equivalence and cultural relevance across dif-
ferent languages. METHODS: The translation process was con-
ducted by a specialist in each target country using the following
standardized methodology: 1) two forward translations by pro-
fessional translators; 2) comparison and reconciliation of the
translations by the specialist in the target country; 3) backward
translation; 4) comparison of source and backward version; 5)
review by a clinician (for the ITSQ only); and 6) comprehension
test on a small sample of the target population diagnosed with
diabetes and undergoing insulin treatment (for the ITSQ only).
RESULTS: Linguistic and conceptual issues emerged during the
translation process. Firstly, when an original item used two adjec-
tives to cover one concept some languages only had one term to
express this. Secondly, some concepts, in particular in relation to
meals, do not exist in certain Indian languages and paraphrases
had to be found to ensure conceptual equivalence with the origi-
nal and appropriateness in the target language. CONCLUSION:
The language versions of the ITSQ and the ETS-Q were estab-
lished according to rigorous translation methodology. The
process aims to ensure conceptual equivalence across different
language versions to facilitate international comparison and
pooling of data. Thus, the result is linguistically validated ques-
tionnaires. The linguistic validation process as a whole supports
the advantage of integrating international feedback on concepts
and wording before a questionnaire is ﬁnalized.
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OBJECTIVES: Little is known about how the public uses the
nicotine patch after it was reclassiﬁed from prescription to over-
the-counter (OTC) status. This observational study describes the
characteristics of consumers who purchase OTC nicotine patches
from pharmacies and to determine factors associated with off-
label use of nicotine patch. METHODS: Prospective, longitudi-
nal study of N = 600 OTC nicotine patch consumers from a
random sample of 30 retail pharmacies throughout San Diego
County. Each subject completed a self-administered, anonymous
questionnaire at the time of purchase and at 2-weeks after using
the patch. Off-label use was deﬁned as intention to smoke while
on the patch or using the patch for harm reduction rather than
quitting. Logistic regression was performed to determine the
factors associated with off-label use. RESULTS: The cohort had
low Fagerstrom nicotine dependence score (mean = 3.58). Sixty-
four percent stated that their physicians were not aware of them
using the patch. Main reasons prompting purchase included self-
initiative (54%), family/friends (20%), physician advice (15%),
and pharmacist’s advice (3%). Eight percent intend to use the
patch for harm reduction rather than quitting. Minorities and
individuals with high income were more likely to engage in
off-label use. Of those who returned the second questionnaire
(N = 155), 78% did not review the self-aid counseling materials
enclosed in the product package. Forty-ﬁve percent reported
smoking cigarettes at 2 weeks, and 8% admitted to using more
than one patch per day. CONCLUSION: A substantial number
of the consumers had low Fagerstrom nicotine dependence scores
and would not have qualiﬁed as for the patch under the prescrip-
tion setting. Most consumers did not review the self-aid materials
even though it was included in the package, and some consumers
intentionally engaged in off-label use of the product. Further
research is needed to devise interventions to ensure proper usage
of OTC nicotine patch by the public.
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OBJECTIVES: To evaluate the cost-effectiveness of PPH com-
pared to MM for treating prolapsed internal haemorrhoids from
the NHS’s perspective. METHODS: A cohort-based model with
a decision tree structure was developed to investigate the cost
effectiveness of PPH in the treatment of haemorrhoids; the
primary outcome was total direct NHS cost and QALYs. Patients
in whom surgical intervention is considered appropriate enter the
model having undergone either a PPH or MM procedure. The
patient then goes through a recovery period during which a
proportion of the patients may suffer a recurrent prolapse. The
severity of the recurrent prolapse determines whether the patient
is able to self-treat or requires further surgery. Those who require
re-surgery are readmitted to hospital and undergo the same pro-
cedure they had on entry to the model. Resource utilisation
associated with procedure cost and post operative complication
was estimated by NHS reference costs 2006. RESULTS: Cost
drivers were identiﬁed as the cost of the stapling device and
reductions in length of stay in the PPH group. QALYs were
driven by reductions in post-operative pain from PPH. Total
direct NHS costs per were 972.66 and 928.66 for PPH and
MM, respectively. PPH vs. MM offers a cost saving of 10.74/
patient due to less length of stay and OR time considering the
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